This program is studying an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis. An inhaled version could make it easier for someone with a Pseudomonas infection to take the drug from home. In addition, the drug, which targets the outer membrane of bacteria, has the potential to be a once-a-day treatment.

Status

Preclinical laboratory studies were completed. No further development in CF is planned at this time.

Sponsor

This program is sponsored by Spexis and partially funded by the Cystic Fibrosis Foundation.